

# chlorothiazide

## 25mg/mL oral mixture\*

© Department of Health, Government of South Australia. All rights reserved

### Note

This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient's medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary,
- Advising consumers of their choice and ensuring informed consent is obtained,
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements

## Dose and Indications

### Treatment of mild to moderate fluid overload states including congestive heart failure and bronchopulmonary dysplasia

#### Mild to moderate hypertension

##### Oral

10mg/kg every twelve hours

Dose may be increased up to 20mg/kg every twelve hours

## Preparation and Administration

##### Oral

The 25mg/mL solution contains:

Dose	5mg	10mg	15mg	20mg	25mg	30mg
Volume	0.2mL	0.4mL	0.6mL	0.8mL	1mL	1.2mL

\* 25mg/mL solution is not commercially available however is manufactured at Women's & Children's Health Network Pharmacy

**ISBN number:**  
**Endorsed by:**  
**Last Revised:**  
**Contact:**

978-1-74243-445.2  
South Australian Maternal & Neonatal Clinical Network  
06/11/12  
South Australian Neonatal Medication Guidelines Workgroup at:  
NeoMed@health.sa.gov.au

# chlorothiazide

## 25mg/mL oral mixture\*

### Adverse Effects

#### Common

Polyuria, hypotension, hyponatraemia, hypokalaemia, hyperuricaemia, hypochloraemic alkalosis, hypomagnesaemia

#### Infrequent

Rash, hyperglycaemia, hypercalcaemia, dyslipidaemia

#### Rare

Vomiting, constipation, diarrhoea, intrahepatic cholestatic jaundice, cholecystitis, pancreatitis, agranulocytosis, aplastic anaemia, haemolytic anaemia, thrombocytopenia, dermatitis, urticaria, photosensitivity, toxic epidermal necrolysis, purpura, necrotising vasculitis

### Monitoring

- > Serum electrolytes, calcium, phosphorus and glucose
- > Urine output
- > Blood pressure

### Practice Points

- > Contraindicated in patients with anuria.
- > Use cautiously in patients with hepatic or renal impairment and patients with significant electrolyte dysfunction (particularly hypercalcaemia)
- > Potassium and sodium depletion is a common side effect and supplementation may be necessary with prolonged therapy
- > Additional potassium loss may occur if given with other drugs that reduce potassium concentrations (e.g. frusemide)
- > Caution may be needed if co-administered with digoxin and cardiotoxicity is more likely in patients with hypokalaemia
- > As chlorothiazide may displace bilirubin from albumin it should be used with caution in neonates with significant jaundice.

### Version control and change history

**PDS reference:** OCE use only

Version	Date from	Date to	Amendment
1.0	November 2012	current	Original version

**ISBN number:**  
**Endorsed by:**  
**Last Revised:**  
**Contact:**

978-1-74243-445.2  
 South Australian Maternal & Neonatal Clinical Network  
 06/11/12  
 South Australian Neonatal Medication Guidelines Workgroup at:  
 NeoMed@health.sa.gov.au